Autologous Protein Solution for Knee Pain in Singapore

Knee osteoarthritis pain often starts quietly, with mild morning stiffness, a dull ache after stairs, or discomfort after longer walks.

Over time, it can affect your ability to train consistently, keep up with work demands, and stay active. If symptoms persist despite physiotherapy and strengthening, your doctor may discuss targeted options such as a knee joint injection consultation as part of a broader plan for knee pain and knee joint injection care in Singapore.

Autologous Protein Solution, often shortened to APS, is an advanced injection option used for knee osteoarthritis pain. It is created from a small sample of your own blood and processed in a clinic to concentrate specific anti-inflammatory proteins and growth factors, then injected into the knee joint as a single intra-articular injection.

The nSTRIDE APS system is a point-of-care kit designed to produce about 2 to 3 cc of APS for knee injection. If you are comparing options, APS is often discussed alongside approaches such as platelet rich plasma injections, depending on your diagnosis, osteoarthritis severity, and activity goals.

Let us take care of your knee pain. Find out more about Autologous Protein Solution today.

What is Autologous Protein Solution APS

Autologous Protein Solution is a biologic injection created from your own blood. It is designed for knee osteoarthritis and is prepared at the point of care using a dedicated processing system.

The nSTRIDE® APS kit is described as a sterile single-use device system that separates anti-inflammatory cytokines and growth factors from whole blood to create an autologous injectable solution.

A simple way to understand APS is that instead of injecting a manufactured medication, APS uses your own blood components, processed in a specific way, to deliver a higher concentration of proteins that may help shift the joint environment away from excessive inflammation and toward better function.

What knee conditions is APS used for

APS is described specifically as an intra articular injection for the treatment of knee osteoarthritis.

It is not designed to treat every cause of knee pain. A knee can be painful because of osteoarthritis, but it can also be painful because of a meniscus tear, ligament injury, tendon overload, or inflammatory arthritis. APS is typically discussed when the diagnosis is primarily knee osteoarthritis and the main goal is to reduce pain and improve function.

In the clinical study summary, APS was studied in people with unilateral knee osteoarthritis graded as Kellgren Lawrence grade 2 or 3, which broadly corresponds to mild to moderate radiographic osteoarthritis.

How APS is different from standard PRP for knee pain

Many patients have heard of PRP, or platelet-rich plasma, for knee pain. APS is related to PRP in that both are derived from your blood, but they are not the same product and they are not designed to concentrate the same components.

APS contains concentrated white blood cells, platelets and plasma proteins in a small volume of plasma.

nSTRIDE APS system on the other hand, contains concentrating anti-inflammatory cytokines and anabolic growth factors to decrease pain and promote cartilage health.

In practical terms, APS is often framed as a blood-derived injection designed to deliver a stronger anti-inflammatory protein profile alongside growth factors, rather than focusing mainly on platelet concentration alone.

The best choice between PRP and APS still depends on your diagnosis, your osteoarthritis severity, your activity goals and the overall treatment plan.

How Autologous Protein Solution is thought to work

Osteoarthritis is not only “wear and tear”. It also involves inflammatory signalling inside the joint. It is a model where inflammatory proteins such as IL-1 and TNF-alpha contribute to cartilage degeneration and knee pain and states that these inflammatory proteins need to be stopped simultaneously to decrease pain and slow cartilage degeneration.

APS is described as introducing higher levels of anti-inflammatory factors that can block these inflammatory cytokines. IL-1 receptor antagonist, often written as IL-1ra and soluble TNF receptors, described as sTNF RI and sTNF RII, are part of the APS output profile.

While inflammatory balance is being restored, APS introduces anabolic growth factors such as IGF-1 and TGF beta 1, which are framed as beneficial for cartilage health.

A patient-friendly way to think about this is:

Osteoarthritis pain is partly driven by inflammation signals inside the joint
APS aims to deliver more of the body’s own “blockers” to calm those signals
This may reduce pain, improve function and support a healthier joint environment over time

Preclinical research findings supporting APS

APS is produced using density based separation followed by filtration-based concentration, with the goal of creating a small volume injectable solution enriched in anti-inflammatory proteins and growth factors. In laboratory settings, APS has been shown to reduce processes associated with cartilage breakdown.

This includes reducing catabolic enzyme production in cartilage cells exposed to inflammatory signals such as IL-1 beta and TNF alpha to:

reduce inflammatory cytokine production from stimulated immune cells
limit destructive changes in cartilage tissue under inflammatory conditions.

Animal research has also been used to explore how APS may influence osteoarthritis-related cartilage changes. In a meniscal tear model in rats, a single intra-articular APS injection was associated with reduced cartilage degeneration compared with saline control.

In a large animal study involving horses with naturally occurring osteoarthritis, APS was associated with improvements in lameness scores compared with saline at two weeks, with owner-reported improvements at later follow-up points.

Don’t let your knee pain slow you down. Take the first step toward stronger, pain-free movement today.

Clinical outcomes reported for APS in knee osteoarthritis

Human studies have evaluated APS specifically for knee osteoarthritis pain and function.

In one safety-focused study involving 11 patients with knee osteoarthritis who received a single intra-articular APS injection, patient-reported outcomes were tracked over time using WOMAC measures, with pain scores showing improvement across follow up.

In that same dataset, higher white blood cell concentration was associated with higher IL 1ra content in the APS product and the ratio of IL 1ra to IL 1 beta was reported to correlate with better WOMAC pain improvement at six months. In this group, 72.7 percent of patients were classified as high responders using OMERACT OARSI criteria at six months.

A larger multicenter double blind randomised placebo controlled pilot study also evaluated APS in 46 patients with unilateral knee osteoarthritis, graded Kellgren Lawrence 2 or 3. Patients received a single ultrasound-guided intra-articular injection of APS or a single saline injection.

At 12 months, the change from baseline WOMAC pain score was reported as 65 percent in the APS group and 41 percent in the saline group, with a reported p-value of 0.02. Safety outcomes were reported as similar between groups, with no significant differences in adverse event frequency, severity, or relatedness.

Overall, these findings suggest APS may improve pain and function in selected patients with mild to moderate knee osteoarthritis, while still recognising that response varies and no injection can guarantee a specific outcome for every individual.

Practical features of APS treatment that matter to patients

APS is designed as a point-of-care treatment, meaning it is prepared in the clinic from a small blood sample and injected during the same visit.

The final injection volume is typically about 2 to 3 cc, delivered directly into the knee joint as a single injection approach. Many clinical protocols describe symptom improvement beginning after one to two weeks and study follow-up suggests benefits may persist for up to 12 months in selected patients. In real-world care, timelines and durability vary depending on osteoarthritis severity, body weight, activity load, biomechanics and how consistently rehabilitation is maintained.

Who may be suitable for Autologous Protein Solution for knee pain in Singapore

APS is usually discussed for people whose knee pain is primarily driven by osteoarthritis and remains limiting despite a structured conservative plan.

You may be a candidate if you have a confirmed diagnosis of knee osteoarthritis, commonly mild to moderate on imaging and persistent pain that limits stairs, walking distance, squats, or sport participation. APS may also be considered if you have tried physiotherapy and strengthening with reasonable consistency but pain remains a barrier and you prefer a biologic option created from your own blood, delivered as a single injection approach.

Selection still needs to be individualised because knee osteoarthritis varies widely in pain drivers and severity.

Who may not be suitable for APS

APS is not intended for every cause of knee pain, so a consultation is needed to confirm knee osteoarthritis is the primary pain source.
APS may be unsuitable or require extra caution if you have:
- Suspected or confirmed infection in the knee or elsewhere
- Unexplained significant swelling or systemic symptoms that need investigation
- Mechanical locking or catching symptoms suggesting a meniscus tear
- Significant knee instability from a ligament injury
- Bleeding disorders or blood thinning medication considerations that affect blood draw or injection safety
- End stage osteoarthritis, where structural collapse dominates symptoms and surgical planning may be more appropriate
Your doctor should review your medical history, medications, examination findings and imaging before advising whether APS fits your situation.

Don’t let your knee pain slow you down. Take the first step toward stronger, pain-free movement today.

What to expect at The Clifford Clinic

Your care pathway begins with a doctor-led assessment.

A detailed symptom map of where pain is felt, what triggers it and how long it has persisted, followed by a focused knee examination assessing range of motion, swelling pattern, tenderness and functional loading tolerance.
Imaging is reviewed when needed, such as X-ray or MRI, to confirm osteoarthritis severity and rule out other causes.
If knee osteoarthritis is confirmed, APS is discussed alongside other injection options such as hyaluronic acid viscosupplementation, corticosteroid injections when appropriate and platelet-rich plasma, depending on your clinical profile.
The goal is to match the injection choice to your knee pathology and your goals rather than defaulting to one option.
You will then receive a practical plan covering what improvement to look for, expected response timeline, what to do in the first two weeks and how to progress strengthening and activity safely.

What happens during APS treatment

APS treatment is typically completed within a single appointment.

A small blood sample is collected, then processed using the nSTRIDE system, which includes a cell separation step using centrifugal force and a concentration step that uses filtration through specialised beads to produce a small volume injectable solution.

The APS is then injected into the knee joint, often using ultrasound guidance which improves accuracy and safety for your anatomy and clinical context. After the injection, you receive clear aftercare instructions and rehabilitation guidance.

Aftercare and recovery timeline

APS is a biologic injection, so the aim is to let the joint settle and respond without a sudden spike in loading.

Many APS protocols advise reducing activity for around 14 days and avoiding activity levels beyond what you were doing before the injection during that period.

In the first 48 to 72 hours, mild soreness, a sense of fullness, or swelling can occur and should gradually settle.

From days 3 to 14, light movement and normal daily activities are usually fine within comfort, while avoiding high-impact loading. After two weeks, strengthening progresses gradually, focusing on quadriceps, hamstrings, glute strength and movement mechanics for stairs and squats.

Longer term, maintaining strength, managing training load and reducing flare triggers are key to preserving gains.

When will APS start to work and how long can it last

APS is often described as starting to improve symptoms after one to two weeks, with clinical follow-up suggesting benefits can persist up to 12 months in selected patients. Some patients improve sooner, others later and durability varies.

Osteoarthritis grade, body weight, activity level, biomechanics and rehabilitation adherence all influence the outcome.

Safety and side effects

Expected short-term side effects can include bruising, local pain, or swelling related to the blood draw and the knee injection itself.

Clinical trial summaries have reported similar adverse event profiles between APS and saline control groups. As with any injection, rare risks include infection or a significant inflammatory reaction.

You should contact the clinic promptly if you develop increasing warmth, fever, rapidly worsening pain, or marked swelling.

APS compared with other knee injections

Hyaluronic acid injections are commonly positioned as viscosupplementation, focusing on lubrication and friction reduction.

APS is positioned as a blood-derived solution that concentrates anti-inflammatory cytokines and growth factors, aiming to reduce inflammatory drivers of osteoarthritis pain and support a healthier joint environment.

Steroid injections may reduce inflammation more quickly in some flares but are typically used as short-term symptom control. PRP approaches vary widely, while APS is specifically designed to concentrate white blood cells, platelets and plasma proteins with emphasis on anti-inflammatory cytokines such as IL-1ra and soluble TNF receptors alongside growth factors.

The best choice depends on diagnosis, osteoarthritis severity, symptom pattern and treatment goals.

Frequently Asked Questions

Is APS the same as stem cell treatment?

APS is described as an autologous protein solution created from your blood that concentrates specific cells and proteins. It is not presented as a stem cell therapy.

How many injections do I need?

Clinical studies demonstrated the effectiveness of one injection, and that one injection can last at least 12 months in the study results. In practice, your response is reviewed, and future planning is individualised.

Can APS cure osteoarthritis?

No. There is no cure for osteoarthritis, but treatment may reduce or relieve pain.

Do I need imaging before APS?

Often yes, because the goal is to confirm osteoarthritis severity and rule out other pain drivers. Your doctor will advise what is necessary.

Can I exercise after the injection?

It is recommended to minimise activity level for 14 days and not exceeding pre injection levels. After that, exercise usually returns in stages with progressive strengthening.

Book an APS consultation for knee pain in Singapore

If you are considering Autologous Protein Solution (APS) for knee pain in Singapore, book a consultation at The Clifford Clinic.

Our doctors will assess whether your symptoms are truly driven by knee osteoarthritis, review your imaging where needed and explain clearly whether APS is suitable for your stage of wear and your activity goals.

You will also receive a structured plan covering alternatives such as hyaluronic acid or PRP where appropriate and a practical recovery and rehabilitation timeline so you know exactly what to do after the injection.

Want to chat?

Social